C17orf51 Inhibitors
C17orf51inhibitors may range from kinase inhibitors, phosphatase inhibitors, and proteasome inhibitors. Kinase inhibitors like LY294002, PD98059, and U0126 function by blocking the catalytic activity of kinases involved in transmitting signals within cells. These signals can govern a wide array of cellular processes including proliferation, survival, and differentiation, all of which could intersect with the functional landscape of C17orf51.
Proteasome inhibitors such as Bortezomib can alter protein degradation pathways, leading to an accumulation of proteins within the cell. This can create a stress response or alter the protein equilibrium, affecting the functional context in which C17orf51 operates. The chemical diversity of these inhibitors reflects the complexity of cellular signaling and the potential multiplicity of mechanisms by which C17orf51 could be regulated or modulated. Each inhibitor operates within the confines of cellular biochemistry to exert an effect on protein function indirectly, without the necessity of direct binding or interaction with C17orf51 itself.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A phosphoinositide 3-kinase (PI3K) inhibitor, which can disrupt downstream signaling that may intersect with C17orf51-related pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An extracellular signal-regulated kinase (ERK) pathway inhibitor, which can alter signaling cascades that could interact with C17orf51. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAP kinase inhibitor, which can modify the MAPK pathway potentially affecting C17orf51's activity or expression. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), which can influence signaling pathways that may regulate C17orf51. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Another PI3K inhibitor that can affect pathways possibly connected to C17orf51's function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can impact cellular growth and proliferation pathways, potentially altering C17orf51 activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
An inhibitor of MEK1/2, which can affect ERK pathway signaling and possibly the function of C17orf51. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
A Src family kinase inhibitor that can disrupt various signaling pathways, potentially affecting C17orf51-related processes. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that can lead to changes in cellular protein levels, possibly influencing C17orf51 stability. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $153.00 $356.00 | 15 | |
An Aurora kinase inhibitor affecting cell division, which could indirectly affect C17orf51's role in the cell cycle. | ||||||